MX2010006795A - Compuestos antitumorales. - Google Patents

Compuestos antitumorales.

Info

Publication number
MX2010006795A
MX2010006795A MX2010006795A MX2010006795A MX2010006795A MX 2010006795 A MX2010006795 A MX 2010006795A MX 2010006795 A MX2010006795 A MX 2010006795A MX 2010006795 A MX2010006795 A MX 2010006795A MX 2010006795 A MX2010006795 A MX 2010006795A
Authority
MX
Mexico
Prior art keywords
antitumoral compounds
antitumoral
compounds
cancer
compound
Prior art date
Application number
MX2010006795A
Other languages
English (en)
Spanish (es)
Inventor
Alberto Rodriguez Vicente
Maria Garranzo Garcia-Ibarrola
Carmen Murcia Perez
Francisco Sanchez Sancho
Maria Del Carmen Cuevas Marchante
Cristina Mateo Urbano
Isabel Digon Juarez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2010006795A publication Critical patent/MX2010006795A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/51—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
MX2010006795A 2007-12-20 2008-12-19 Compuestos antitumorales. MX2010006795A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07123882 2007-12-20
PCT/EP2008/068065 WO2009080769A1 (en) 2007-12-20 2008-12-19 Antitumoral compounds

Publications (1)

Publication Number Publication Date
MX2010006795A true MX2010006795A (es) 2010-10-26

Family

ID=40580474

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2010006795A MX2010006795A (es) 2007-12-20 2008-12-19 Compuestos antitumorales.
MX2010006796A MX2010006796A (es) 2007-12-20 2008-12-19 Compuestos antitumorales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2010006796A MX2010006796A (es) 2007-12-20 2008-12-19 Compuestos antitumorales.

Country Status (26)

Country Link
US (4) US8710264B2 (enExample)
EP (3) EP2231633B1 (enExample)
JP (3) JP5529038B2 (enExample)
KR (3) KR101639772B1 (enExample)
CN (4) CN102190643B (enExample)
AT (1) ATE549313T1 (enExample)
AU (2) AU2008341671B2 (enExample)
BR (2) BRPI0821116B8 (enExample)
CA (2) CA2715203C (enExample)
CY (1) CY1117245T1 (enExample)
DK (2) DK2231590T3 (enExample)
ES (3) ES2384420T3 (enExample)
HR (2) HRP20140015T1 (enExample)
IL (3) IL206396A (enExample)
MX (2) MX2010006795A (enExample)
MY (3) MY148651A (enExample)
NZ (3) NZ597526A (enExample)
PL (2) PL2231590T3 (enExample)
PT (2) PT2231590E (enExample)
RS (2) RS53140B (enExample)
RU (3) RU2493147C2 (enExample)
SG (2) SG170778A1 (enExample)
SI (2) SI2231590T1 (enExample)
UA (3) UA106967C2 (enExample)
WO (2) WO2009080769A1 (enExample)
ZA (3) ZA201004017B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi
WO2013103155A1 (en) * 2012-01-05 2013-07-11 Kao Corporation Agent for reduction of sensory irritation
MA38588B1 (fr) 2013-04-16 2018-04-30 Idorsia Pharmaceuticals Ltd Dérivés bi-aromatiques antibactériens
GB201309807D0 (en) * 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
CN108467378A (zh) * 2017-02-23 2018-08-31 复旦大学 一种二氢吡喃酮类化合物及其制备方法和用途
LT3615544T (lt) 2017-04-27 2023-05-10 Pharma Mar S.A. Priešnavikiniai junginiai
TWI824043B (zh) 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
JPH06504547A (ja) * 1990-12-28 1994-05-26 ジョージア・テック・リサーチ・コーポレーション ペプチドケトアミド、ケト酸およびケトエステル
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
ZA938019B (en) 1992-11-13 1995-04-28 Upjohn Co Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating HIV and other retroviruses
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5681847A (en) * 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
US5834506A (en) 1996-11-01 1998-11-10 Warner-Lambert Company Dihydropyrones with improved antiviral activity
US5840974A (en) * 1996-12-04 1998-11-24 Britisch Biotech Pharmaceuticals, Ltd. Metalloproteinase inhibitors
US6380400B1 (en) 1998-09-11 2002-04-30 Victor Fedij Methods of making dihydropyrone HIV protease inhibitors
US6528510B1 (en) 1998-09-11 2003-03-04 Warner-Lambert Company HIV protease inhibitors
AU2000241948A1 (en) * 2000-04-04 2001-10-15 Novartis Ag Method for treating cells resistant to antineoplastic agents
MXPA04008577A (es) * 2002-03-04 2005-07-13 Aton Pharma Inc Metodos para inducir diferenciacion terminal.
AU2004263287B2 (en) * 2003-07-25 2009-02-12 Novartis Ag Substituted lactams and their use as anti-cancer agents
RU2006142690A (ru) * 2004-06-03 2008-06-10 Козан Байосайенсиз Инкорпорейтед (Us) Соединения лептомицина
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
WO2007014423A1 (en) * 2005-08-02 2007-02-08 Medvet Science Pty, Ltd. Exercise apparatus
EP2404912A3 (en) 2006-06-16 2012-07-25 Pharma Mar S.A. Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
HRP20140015T1 (hr) 2007-12-20 2014-02-14 Pharma Mar, S.A. Antitumorski spojevi

Also Published As

Publication number Publication date
NZ586012A (en) 2011-11-25
US20100280108A1 (en) 2010-11-04
BRPI0821114B1 (pt) 2021-09-08
JP2014133752A (ja) 2014-07-24
EP2231590B1 (en) 2012-03-14
HK1147990A1 (en) 2011-08-26
MY155342A (en) 2015-10-15
BRPI0821114B8 (pt) 2021-11-09
RU2493147C2 (ru) 2013-09-20
IL206397A (en) 2014-01-30
JP5529038B2 (ja) 2014-06-25
JP5860088B2 (ja) 2016-02-16
CN101903367A (zh) 2010-12-01
IL206396A (en) 2014-05-28
CN102174058A (zh) 2011-09-07
US9187445B2 (en) 2015-11-17
HK1180678A1 (en) 2013-10-25
IL206396A0 (en) 2010-12-30
US20120041063A2 (en) 2012-02-16
EP2231633B1 (en) 2013-10-30
JP5727228B2 (ja) 2015-06-03
IL206397A0 (en) 2010-12-30
MX2010006796A (es) 2010-10-26
UA106967C2 (uk) 2014-11-10
MY164533A (en) 2017-12-29
RU2013112003A (ru) 2014-08-20
DK2231590T3 (da) 2012-07-09
US20150344454A1 (en) 2015-12-03
ES2442140T3 (es) 2014-02-25
JP2011506575A (ja) 2011-03-03
CN102190643A (zh) 2011-09-21
PL2231633T3 (pl) 2014-03-31
SI2231590T1 (sl) 2012-10-30
RU2528393C9 (ru) 2015-01-10
EP2231633A1 (en) 2010-09-29
EP2597091A1 (en) 2013-05-29
IL229594A (en) 2016-02-29
AU2008341670B2 (en) 2012-04-19
PT2231590E (pt) 2012-06-25
UA104281C2 (ru) 2014-01-27
RU2528393C1 (ru) 2014-09-20
ZA201106371B (en) 2013-05-29
CN101903367B (zh) 2015-08-05
BRPI0821116B1 (pt) 2020-02-18
JP2011506578A (ja) 2011-03-03
CN101903337A (zh) 2010-12-01
HK1147998A1 (en) 2011-08-26
RS52343B (sr) 2012-12-31
SI2231633T1 (sl) 2014-02-28
ES2384420T3 (es) 2012-07-04
AU2008341671B2 (en) 2012-07-26
KR20150076265A (ko) 2015-07-06
SG170779A1 (en) 2011-05-30
HRP20120464T1 (hr) 2012-07-31
ZA201004018B (en) 2011-12-28
US9827257B2 (en) 2017-11-28
CA2710087A1 (en) 2009-07-02
BRPI0821116A2 (pt) 2015-08-11
AU2008341670A1 (en) 2009-07-02
CN101903337B (zh) 2013-12-18
KR101541436B1 (ko) 2015-08-03
IL229594A0 (en) 2014-01-30
US8710264B2 (en) 2014-04-29
RS53140B (sr) 2014-06-30
CN102190643B (zh) 2015-02-25
RU2010130180A (ru) 2012-01-27
KR101579553B1 (ko) 2015-12-22
RU2489429C2 (ru) 2013-08-10
WO2009080761A1 (en) 2009-07-02
BRPI0821116B8 (pt) 2021-05-25
SG170778A1 (en) 2011-05-30
CA2710087C (en) 2015-06-02
US20150342972A1 (en) 2015-12-03
KR101639772B1 (ko) 2016-07-15
MY148651A (en) 2013-05-15
UA119963C2 (uk) 2019-09-10
US9750759B2 (en) 2017-09-05
PT2231633E (pt) 2014-01-20
WO2009080769A1 (en) 2009-07-02
EP2231590B9 (en) 2012-08-15
DK2231633T3 (da) 2014-01-20
HRP20140015T1 (hr) 2014-02-14
CA2715203C (en) 2015-09-08
BRPI0821114A2 (pt) 2015-06-16
EP2597091B1 (en) 2016-04-20
AU2008341671A1 (en) 2009-07-02
ATE549313T1 (de) 2012-03-15
KR20100125226A (ko) 2010-11-30
ES2578606T3 (es) 2016-07-28
EP2231590A1 (en) 2010-09-29
PL2231590T3 (pl) 2012-09-28
US20110034549A1 (en) 2011-02-10
ZA201004017B (en) 2011-12-28
RU2010130253A (ru) 2012-01-27
NZ586013A (en) 2012-02-24
KR20100100979A (ko) 2010-09-15
NZ597526A (en) 2012-06-29
CY1117245T1 (el) 2017-04-05
CA2715203A1 (en) 2009-07-02

Similar Documents

Publication Publication Date Title
GEP201706703B (en) Boronate ester compounds and pharmaceutical compositions thereof
HUE059861T2 (hu) N-Szubsztituált 2,5-dioxo-azolin vegyületek a rák kezelésében való felhasználásra
GEP20125702B (en) Benzimidazole derivatives
TW200740776A (en) N-phenylbenzotriazolyl c-kit inhibitors
MX2010006143A (es) Azolilmetiloxiranos, su uso y agentes que lo contienen.
MX2009009290A (es) Compuestos activos en ppar.
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
MX2009011578A (es) 6-fenilpirimidinonas como moduladores de pim.
SG170778A1 (en) Antitumoral compounds
TN2011000291A1 (en) Purine compounds
UA103625C2 (en) 5-hetrocyclylalkyl-3-hydroxy-2-phenylcyclopent-2-enons as herbicides
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
DE502008001158D1 (en) Benzimidazolderivate
TW200800969A (en) Compounds
MX2009009916A (es) Tetrahidroquinolinas sustituidas.
TN2010000094A1 (en) Novel herbicides
MX2009009917A (es) Derivados de tetrahidroquinolina y su uso para el tratamiento de cancer.
WO2010149688A3 (en) Antitumoral compounds
GB0620005D0 (en) Compounds
TW200700423A (en) Heterobicyclic acrylamides
UA91250C2 (en) 4-oxadiazolyl-piperidine compounds and use thereof

Legal Events

Date Code Title Description
FG Grant or registration